Binds Receptor (e.g., Transferrin Receptor, Fc Receptor, Dihydropyridine Receptor, Il-2 Receptor, Etc.) Patents (Class 530/388.22)
-
Patent number: 8536312Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.Type: GrantFiled: December 28, 2010Date of Patent: September 17, 2013Assignee: Adnagen GmbHInventors: Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
-
Patent number: 8536308Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.Type: GrantFiled: July 12, 2010Date of Patent: September 17, 2013Assignee: Merck Patent GmbHInventors: Jeffrey Way, Yuan Liu
-
Patent number: 8536118Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.Type: GrantFiled: September 29, 2009Date of Patent: September 17, 2013Assignee: Genentech, Inc.Inventors: Monica Kong-Beltran, Dineli M. Wickramasinghe
-
Publication number: 20130236459Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.Type: ApplicationFiled: February 27, 2013Publication date: September 12, 2013Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
-
Patent number: 8530173Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: GrantFiled: June 1, 2011Date of Patent: September 10, 2013Assignee: The Brigham and Women's Hospital, Inc.Inventor: Richard T. Lee
-
Patent number: 8529902Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 17, 2003Date of Patent: September 10, 2013Assignee: Genmab A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Patent number: 8530627Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: July 3, 2008Date of Patent: September 10, 2013Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Publication number: 20130230899Abstract: It is intended to ameliorate arteriosclerosis or arteriosclerotic disease through a pharmacological mechanism that reduces the size of the arteriosclerotic lesion. The agent of the present invention comprises a complex comprising an antibody binding to folate receptor ? (FR?) and a cytotoxin or a cytotoxic agent conjugated with the antibody, or the antibody as an active ingredient.Type: ApplicationFiled: November 8, 2011Publication date: September 5, 2013Inventors: Chuwa Tei, Masaaki Miyata, Yuko Furusyo, Takami Matsuyama, Taku Nagai
-
Publication number: 20130230534Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.Type: ApplicationFiled: May 9, 2013Publication date: September 5, 2013Applicant: MEDAREX, INC.Inventors: JOSEPHINE M. CARDARELLI, ALISON WITTE, MOHAN SRINIVASAN
-
Patent number: 8524236Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: September 16, 2005Date of Patent: September 3, 2013Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 8524672Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: August 19, 2011Date of Patent: September 3, 2013Assignee: Biogen Idec MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson
-
Patent number: 8524865Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.Type: GrantFiled: May 29, 2007Date of Patent: September 3, 2013Assignee: Genentech, Inc.Inventors: Allen J. Ebens, Jr., Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
-
Patent number: 8524867Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.Type: GrantFiled: August 14, 2007Date of Patent: September 3, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
-
Publication number: 20130224220Abstract: The present invention relates to an antibody, particularly a monoclonal antibody, which binds to the ErbB3 receptor, compositions comprising such an antibody as well as methods using such an antibody.Type: ApplicationFiled: September 12, 2011Publication date: August 29, 2013Applicant: MEDIAPHARMA S.R.L.Inventors: Raffaella Muraro, Stefano Iacobelli, Nicola Tinari, Sara Traini, Gianluca Sala
-
Patent number: 8518403Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: GrantFiled: July 15, 2005Date of Patent: August 27, 2013Assignee: Amgen Research (Munich) GmbHInventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Raum
-
Patent number: 8512704Abstract: The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.Type: GrantFiled: July 30, 2010Date of Patent: August 20, 2013Assignee: Genentech, Inc.Inventors: Kerstin Jahn-Hofmann, Sannah Zoffmann Jensen, Hugues Matile, Cristiano Migliorini, Haiyan Wang
-
Patent number: 8513390Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: April 25, 2012Date of Patent: August 20, 2013Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Patent number: 8512702Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: December 14, 2011Date of Patent: August 20, 2013Assignee: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Patent number: 8513388Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.Type: GrantFiled: June 30, 2011Date of Patent: August 20, 2013Assignee: Genentech, Inc.Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
-
Publication number: 20130209365Abstract: Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.Type: ApplicationFiled: August 30, 2011Publication date: August 15, 2013Applicant: Academia SinicaInventors: Han-Chung Wu, Ruei-Min Lu
-
Publication number: 20130209481Abstract: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.Type: ApplicationFiled: July 22, 2011Publication date: August 15, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Yu Zhou, James D. Marks
-
Patent number: 8501427Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: GrantFiled: January 23, 2008Date of Patent: August 6, 2013Assignee: University College Cardiff Consultants LimitedInventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
-
Patent number: 8497246Abstract: The invention provides methods for treating or diagnosing CNS disorders by systemic administration of therapeutic or diagnostic protein compositions that are capable of crossing the blood-brain barrier, in some embodiments in both directions, while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood-brain barrier via one or more endogenous receptor-mediated transport systems. Also provided are methods for manufacturing the compositions used in the methods described herein.Type: GrantFiled: August 20, 2007Date of Patent: July 30, 2013Assignee: Armagen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Patent number: 8496937Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.Type: GrantFiled: March 30, 2010Date of Patent: July 30, 2013Assignees: Edimer Pharmaceuticals, Inc., Universite de LausanneInventors: Pascal Schneider, Nathalie Dunkel, Stephane Demotz
-
Publication number: 20130189281Abstract: The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.Type: ApplicationFiled: September 27, 2012Publication date: July 25, 2013Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20130189252Abstract: The present application relates to antibodies, such as monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, for the treatment and diagnosis of pain and other neuroinflammatory conditions associated with the Receptor for Advanced Glycation End Products (RAGE).Type: ApplicationFiled: March 15, 2013Publication date: July 25, 2013Inventors: Marina I. Strakhova, Jill-Desiree Brederson
-
Publication number: 20130189271Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: ApplicationFiled: May 27, 2011Publication date: July 25, 2013Applicant: GENMAB A/SInventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce I. Meesters, Janine Schuurman, Edward Norbert Van Den Brink
-
Publication number: 20130189283Abstract: Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: September 22, 2011Publication date: July 25, 2013Applicant: AMGEN INC.Inventors: Kenneth W. Walker, Frederick W. Jacobsen, Taruna Arora
-
Patent number: 8491914Abstract: Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.Type: GrantFiled: December 9, 2010Date of Patent: July 23, 2013Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8492119Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.Type: GrantFiled: April 27, 2010Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki
-
Publication number: 20130183319Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.Type: ApplicationFiled: January 18, 2013Publication date: July 18, 2013Applicant: U3 PHARMA GMBHInventor: U3 PHARMA GMBH
-
Publication number: 20130183320Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.Type: ApplicationFiled: January 18, 2013Publication date: July 18, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Patent number: 8487083Abstract: The invention pertains to the field of medicine, particularly to methods for suppressing the growth of tumors, which comprise blocking the pathological pathway of human fibroblast growth factor/receptor 1 (domains II and IIIc), and for diagnosing malignant neoplasms leading to an excessive proliferation of tumor cells and to the formation of new vessels accompanied by the growth of primary tumors and metastases. This pathway also represents an independent mechanism of tumor resistance to preparations acting on other pathological pathways. Blocking the aforementioned pathway using various substances that neutralize the receptor by bonding only with domains II and IIIc thereof results in the interruption or slow-down of tumor growth. This receptor can also be used as a target for delivery of diagnostic agents being largely present in tumor cells. The invention enables developing new agents for diagnosing and treating diseases related to excessive proliferation and neovascularization.Type: GrantFiled: June 30, 2009Date of Patent: July 16, 2013Assignee: OOO “Oncomax”Inventor: Ilya Valer'evich Tsimafeyeu
-
Publication number: 20130177574Abstract: Provided herein are compositions comprising anti-HLA-Ib antibodies as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies (monoclonal antibodies or mixed monoclonal antibodies, recombinant or chimeric or humanized or human antibodies) strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies (monoclonal or mixed monoclonal antibodies; recombinant, chimeric, humanized or human antibodies) strongly mimic IVIg in immunomodulatory or immunosuppressive activities.Type: ApplicationFiled: January 11, 2012Publication date: July 11, 2013Applicant: PAUL I. TERASAKI FOUNDATION LABORATORYInventors: Mepur H. Ravindranath, Paul I. Terasaki
-
Patent number: 8481683Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: GrantFiled: November 30, 2007Date of Patent: July 9, 2013Assignee: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Patent number: 8481688Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.Type: GrantFiled: May 11, 2011Date of Patent: July 9, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: Zhigang Weng, William M. Winston, Jr., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
-
Patent number: 8481687Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: GrantFiled: April 8, 2011Date of Patent: July 9, 2013Assignee: Aveo Pharmaceuticals, Inc.Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Patent number: 8475793Abstract: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: GrantFiled: February 6, 2009Date of Patent: July 2, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Rene De Waal Malefyt, Leonard G. Presta
-
Publication number: 20130164309Abstract: The present invention provides anti-TCblR antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders.Type: ApplicationFiled: July 20, 2012Publication date: June 27, 2013Applicant: The Research Foundation of State University of New YorkInventors: Edward V. Quadros, Jeffrey M. Sequeira
-
Publication number: 20130164300Abstract: The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.Type: ApplicationFiled: September 5, 2012Publication date: June 27, 2013Inventors: Isabelle TEULON ET AL, André Pelegrin
-
Patent number: 8470324Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.Type: GrantFiled: September 27, 2012Date of Patent: June 25, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
-
Publication number: 20130156786Abstract: The present invention relates to a peptide or peptide complex binding to ?2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting ?2 integrin and a screening method.Type: ApplicationFiled: August 30, 2011Publication date: June 20, 2013Applicant: SANOFIInventors: Carsten Corvey, Horst Blum, Béatrice Cameron, Tarik Dabdoubi, Stephanie Decary, Nicolas Baurin, David Papin, Christian Lange
-
Patent number: 8465741Abstract: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.Type: GrantFiled: September 14, 2007Date of Patent: June 18, 2013Assignee: MMRGlobal, Inc.Inventors: Gerhard Frey, Bruce E. Kimmel, Abraham Anderson
-
Patent number: 8465737Abstract: Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.Type: GrantFiled: April 12, 2007Date of Patent: June 18, 2013Assignee: The Regents of the University of ColoradoInventors: Xiaojiang Chen, Vernon Michael Holers
-
Publication number: 20130149313Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ? and advanced glycation-end-products.Type: ApplicationFiled: November 27, 2012Publication date: June 13, 2013Applicants: ABBOTT LABORATORIES, ABBOTT GMBH & CO. KGInventors: ABBOTT GMBH & CO. KG, ABBOTT LABORATORIES
-
Patent number: 8461304Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: June 9, 2010Date of Patent: June 11, 2013Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Patent number: 8460668Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.Type: GrantFiled: February 12, 2010Date of Patent: June 11, 2013Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
-
Patent number: 8460667Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.Type: GrantFiled: July 13, 2007Date of Patent: June 11, 2013Assignee: SanofiInventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
-
Patent number: 8460669Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.Type: GrantFiled: May 12, 2011Date of Patent: June 11, 2013Assignee: Academia SinicaInventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
-
Patent number: RE44389Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: October 17, 2012Date of Patent: July 23, 2013Assignee: Hoffman-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt